Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. (MDGL)
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am
Check Earnings Report
US:NASDAQ Investor Relations:
madrigalpharma.com
Company Research
Source: GlobeNewswire
CONSHOHOCKEN, Pa., April 16, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced that the company granted equity awards to 7 new employees, in each case with a grant date of April 15, 2024, as equity inducement awards under the terms of the company's 2023 Inducement Plan. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The equity awards were granted as inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, options to purchase 1,979 shares of Madrigal’s common stock, and in the aggregate 4,078 time-based restricted stock units. All options granted have an exercise price of $231.37 per share, and vest as follows (i) 25% of the option shares will vest on the first anniversary of the date of grant and (ii) 6.25% of the option shares shall vest on each q
Show less
Read more
Impact Snapshot
Event Time:
MDGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDGL alerts
High impacting Madrigal Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
MDGL
News
- Madrigal Statement on the Passing of Dr. Stephen HarrisonGlobeNewswire
- Madrigal: 2 Challenges To Overcome To Maintain NASH 'First Mover' Advantage [Seeking Alpha]Seeking Alpha
- Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024 [Yahoo! Finance]Yahoo! Finance
- Madrigal Pharmaceuticals to Release First-Quarter 2024 Financial Results and Host Webcast on May 7, 2024GlobeNewswire
- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) is now covered by analysts at Bank of America Co.. They set an "underperform" rating and a $150.00 price target on the stock.MarketBeat